| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 13.13 mm | 13.13 mm | 13.13 mm | 13.13 mm | 13.13 mm | 13.13 mm |
| Cash burn (monthly) | 284.67 k | (no burn) | 3.40 mm | 3.93 mm | 2.36 mm | 2.90 mm |
| Cash used (since last report) | 1.44 mm | n/a | 17.19 mm | 19.92 mm | 11.97 mm | 14.69 mm |
| Cash remaining | 11.69 mm | n/a | -4.07 mm | -6.80 mm | 1.15 mm | -1.56 mm |
| Runway (months of cash) | 41.0 | n/a | -1.2 | -1.7 | 0.5 | -0.5 |
| 13F holders | Current |
|---|---|
| Total holders | 35 |
| Opened positions | 20 |
| Closed positions | 4 |
| Increased positions | 2 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 671.36 mm |
| Total shares | 20.17 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Yair Chaim Schindel | 7.39 mm | $20.92 mm |
| Biotechnology Value Fund L P | 3.83 mm | $0.00 |
| LVP Life Science Ventures Iii | 3.12 mm | $0.00 |
| Forward Ventures V | 2.57 mm | $0.00 |
| Vanguard | 954.49 k | $220.49 mm |
| Stonepine Capital Management | 500.00 k | $115.70 mm |
| Aisling Capital IV | 288.57 k | $0.00 |
| Aisling Capital Management | 288.57 k | $66.37 mm |
| Geode Capital Management | 250.01 k | $57.87 mm |
| Renaissance Technologies | 245.40 k | $56.79 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 25 Nov 24 | Royston Ivor | Common Stock | Option exercise | Acquire M | No | No | 0 | 25,219 | 0.00 | 839,741 |
| 25 Nov 24 | Royston Ivor | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 25,219 | 0.00 | 50,438 |
| 25 Nov 24 | Pomerantz Roger | Common Stock | Option exercise | Acquire M | No | No | 0 | 9,034 | 0.00 | 126,478 |
| 25 Nov 24 | Pomerantz Roger | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 9,034 | 0.00 | 18,069 |
| 25 Aug 24 | Pomerantz Roger | Common Stock | Option exercise | Acquire M | No | No | 0 | 9,034 | 0.00 | 117,444 |
| 25 Aug 24 | Pomerantz Roger | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 9,034 | 0.00 | 27,103 |
| 25 Aug 24 | Royston Ivor | Common Stock | Option exercise | Acquire M | No | No | 0 | 25,219 | 0.00 | 814,522 |
| 25 Aug 24 | Royston Ivor | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 25,219 | 0.00 | 75,657 |
| 20 Jun 24 | Samuel Lafayette Murphy | Stock Option Common Stock | Grant | Acquire A | No | No | 0.569 | 50,000 | 28.45 k | 50,000 |
